Empower Clinics (CSE: CBDT) this morning announced that it has secured a medical device establishment license (MDEL). The status enables the firm to sell its KAI Saliva COVID-19 PCR test kits within Canada.
The MDEL status effectively enables the company to import, distribute, and sell KAI Saliva test kits, as part of its focus on the ongoing pandemic. The saliva test kits reportedly are approved for FDA EUA use, while also containing the CE Mark, enabling the sale of the test kits in the European Union, while also being approved by Health Canada.
The kit is reportedly specifically geared towards use for travelers, enabling a means of obtaining and conducting an RT-PCR test prior to arriving or coming back to Canada, or other regions that have similar travel requirements. The kit is reportedly focused on providing a home-based, self-administered test to make it travel easier for its users.
The company has partnered with MediPro Canada to use their approved MDEL status for the sale of the test kits. While the company has applied for its own MDEL, the company in the interim appears to be going through MediPro to enable the generation of sales until it receives its own license.
Financial aspects of the arrangement were not provided.
Empower Clinics last traded at $0.48 on the CSE.
Information for this briefing was found via Sedar, and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.